CLIENT NEWS
- Andera Partners participates in the $138 Million Series C Financing of Amolyt Pharma led by Sofinnova Partners and co-led by Intermediate Capital Group09 January 2023
- Proteros receives minority investment from private equity firm Inflexion09 January 2023
- Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound09 January 2023
- InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients05 January 2023
- Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced05 January 2023
- Abivax Publishes Novel Data with Respect to Obefazimod’s Anti-Inflammatory Mechanism of Action05 January 2023
- LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles03 January 2023
- MAINZ BIOMED PROVIDES YEAR-END 2022 CORPORATE REVIEW03 January 2023
- Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia03 January 2023
- Destiny Pharma announces year end Trading Update Good progress across all key projects in 202222 December 2022